Related Experiment Video

Updated: Dec 17, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.3K

Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies

Maria Cancio1, Rachele Ciccocioppo2, Patricia R M Rocco3

  • 1Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Cytotherapy
|June 23, 2020
PubMed

Insights

New treatments are needed for severe COVID-19. This study explores Cytokine Release Syndrome, Immune Reconstitution Inflammatory Syndrome, and Secondary Hemophagocytic Lymphohistiocytosis as potential therapeutic targets for COVID-19.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Oncology

Background:

  • Coronavirus disease 2019 (COVID-19) poses a significant global health challenge with no approved treatments.
  • Severe COVID-19 cases exhibit immune dysfunction, necessitating novel therapeutic strategies.
  • Existing treatments for inflammatory syndromes offer potential parallels for COVID-19 management.

Purpose of the Study:

  • To explore the potential of Cytokine Release Syndrome (CRS), Immune Reconstitution Inflammatory Syndrome (IRIS), and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) as therapeutic targets for COVID-19.
  • To discuss the management of these inflammatory disorders and their relevance to COVID-19.
  • To review current cellular therapies being evaluated for COVID-19 and its symptoms.

Main Methods:

  • Literature review and comparative analysis of clinical and laboratory characteristics of CRS, IRIS, sHLH, and COVID-19.
  • Discussion of management strategies for these inflammatory syndromes.
  • Evaluation of current cellular therapies in the context of COVID-19 treatment.

Main Results:

  • CRS, IRIS, and sHLH share clinical and laboratory features with severe COVID-19.
  • These inflammatory syndromes represent potential avenues for therapeutic exploration in COVID-19 clinical trials.
  • Current cellular therapies are under investigation for managing COVID-19 and associated symptoms.

Conclusions:

  • The shared characteristics between CRS, IRIS, sHLH, and COVID-19 suggest these inflammatory syndromes could inform novel COVID-19 treatment strategies.
  • Further investigation into these parallels may lead to effective therapeutic options for severe COVID-19.
  • Cellular therapies show promise for managing COVID-19 and its complications.
Keywords:
COVID-19CRSHLHIRISSARS-CoV-2cellular therapycytokine releasehyperimmune responseimmunotherapy

More Related Videos

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

60
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.8K

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
811
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
15.4K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
109
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
351